CA2868534A1 - Compositions et traitements bases sur la modulation de la cadherine - Google Patents
Compositions et traitements bases sur la modulation de la cadherine Download PDFInfo
- Publication number
- CA2868534A1 CA2868534A1 CA2868534A CA2868534A CA2868534A1 CA 2868534 A1 CA2868534 A1 CA 2868534A1 CA 2868534 A CA2868534 A CA 2868534A CA 2868534 A CA2868534 A CA 2868534A CA 2868534 A1 CA2868534 A1 CA 2868534A1
- Authority
- CA
- Canada
- Prior art keywords
- cadherin
- wound
- protein
- optionally
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616393P | 2012-03-27 | 2012-03-27 | |
| US61/616,393 | 2012-03-27 | ||
| US13/844,553 US20140274872A1 (en) | 2013-03-15 | 2013-03-15 | Compositions and treatments based on cadherin modulation |
| US13/844,553 | 2013-03-15 | ||
| PCT/US2013/033948 WO2013148736A1 (fr) | 2012-03-27 | 2013-03-26 | Compositions et traitements basés sur la modulation de la cadhérine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2868534A1 true CA2868534A1 (fr) | 2013-10-03 |
Family
ID=48184448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2868534A Abandoned CA2868534A1 (fr) | 2012-03-27 | 2013-03-26 | Compositions et traitements bases sur la modulation de la cadherine |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2831233A1 (fr) |
| JP (1) | JP2015513905A (fr) |
| CN (1) | CN104736709A (fr) |
| CA (1) | CA2868534A1 (fr) |
| WO (1) | WO2013148736A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
| CN105250334A (zh) * | 2015-10-29 | 2016-01-20 | 广州赛莱拉干细胞科技股份有限公司 | 一种改善皮肤的制剂及其制备方法 |
| US11820981B2 (en) | 2016-09-14 | 2023-11-21 | Agency For Science, Technology And Research | Modulation of TJP1 expression to regulate regeneration of heart cells |
| WO2020045652A1 (fr) * | 2018-08-31 | 2020-03-05 | 株式会社 資生堂 | Procédé de détermination de l'état de la peau ou de l'activité cellulaire de cellules cutanées, et procédé de criblage pour activateurs de cellules cutanées |
| EP4402264A4 (fr) * | 2021-09-16 | 2025-10-15 | Agency Science Tech & Res | Modulation de l'expression de tjp1 pour traiter des maladies hépatiques |
| CN117919451B (zh) * | 2024-03-21 | 2024-07-05 | 中国人民解放军军事科学院军事医学研究院 | 与桥粒芯糖蛋白2相关的生物材料的应用及抑制骨再生病理性亢进的药物 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US623499A (en) | 1899-04-18 | Leasuring-can | ||
| US4655767A (en) | 1984-10-29 | 1987-04-07 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
| US4940456A (en) | 1987-02-10 | 1990-07-10 | Dan Sibalis | Electrolytic transdermal delivery of proteins |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5749847A (en) | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5147296A (en) | 1988-10-03 | 1992-09-15 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5169382A (en) | 1988-10-03 | 1992-12-08 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5064655A (en) | 1989-02-24 | 1991-11-12 | Liposome Technology, Inc. | Liposome gel composition and method |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US5484604A (en) | 1990-07-21 | 1996-01-16 | Chatfield Pharmaceuticals Limited | Cross-linked alginate transdermal medicine delivery devices |
| US5362308A (en) | 1990-09-25 | 1994-11-08 | Rutgers, The State University Of New Jersey | Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes |
| US5320850A (en) | 1990-10-29 | 1994-06-14 | Alza Corporation | Transdermal delivery of the gestogen ST-1435 and devices therefor |
| US5279544A (en) | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
| CA2097163C (fr) | 1992-06-01 | 2002-07-30 | Marianna Foldvari | Timbre topique pour administration d'un medicament liposomal |
| KR0134151B1 (ko) | 1994-05-23 | 1998-04-14 | 이형도 | 인슐린 패치 |
| JPH0912448A (ja) | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
| ATE255450T1 (de) | 1995-06-09 | 2003-12-15 | Hisamitsu Pharmaceutical Co | Matrix für iontophorese |
| US6041253A (en) | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
| JP2002515786A (ja) | 1996-06-28 | 2002-05-28 | ソントラ メディカル,エル.ピー. | 経皮輸送の超音波増強 |
| US5910306A (en) | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
| FR2755842B1 (fr) | 1996-11-19 | 1999-04-23 | Lhd Lab Hygiene Dietetique | Procede de mesure de la resistance electrique cutanee d'un patient soumis a une administration transdermique de medicament |
| GB9708066D0 (en) | 1997-04-22 | 1997-06-11 | Woolcombers Group Plc | Compositions and their use |
| TW368420B (en) | 1997-11-04 | 1999-09-01 | Genetronics Inc | Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum |
| AU1800099A (en) | 1997-11-25 | 1999-06-15 | Theratech, Inc. | Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties |
| US6575956B1 (en) | 1997-12-31 | 2003-06-10 | Pharmasonics, Inc. | Methods and apparatus for uniform transcutaneous therapeutic ultrasound |
| EP1045714A1 (fr) | 1998-01-08 | 2000-10-25 | Sontra Medical, L.P. | Transport transdermique par sonophorese ameliore |
| CA2265119C (fr) | 1998-03-13 | 2002-12-03 | Cygnus, Inc. | Biocapteur et systeme d'echantillonnage iontophoresique et methodes d'utilisation de ceux-ci |
| US7004933B2 (en) | 1998-05-29 | 2006-02-28 | Light Bioscience L.L.C. | Ultrasound enhancement of percutaneous drug absorption |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| DE19850517B4 (de) | 1998-11-03 | 2004-02-12 | Lts Lohmann Therapie-Systeme Ag | Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall |
| FR2785544B1 (fr) | 1998-11-09 | 2001-01-05 | Lhd Lab Hygiene Dietetique | Electrode de transfert d'un courant electrique traversant la peau d'un patient |
| US5983135A (en) | 1998-12-24 | 1999-11-09 | Avrahami; Zohar | Transdermal delivery of fine powders |
| DK1146908T3 (da) | 1999-01-27 | 2005-10-10 | Becker David Dr | Formuleringer omfattende antisense-nukleotider mod connexiner |
| DK1189660T3 (da) | 1999-06-08 | 2006-08-21 | Altea Therapeutics Corp | Apparat til mikroperforering af biologiske membraner ved hjælp af tyndfilms-vævsgrænseflade-anordninger samt fremgangsmåde til fremstilling deraf |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6512950B2 (en) | 2000-02-18 | 2003-01-28 | University Of Utah Research Foundation | Methods for delivering agents using alternating current |
| US6706032B2 (en) | 2000-06-08 | 2004-03-16 | Massachusetts Institute Of Technology | Localized molecular and ionic transport to and from tissues |
| US6487447B1 (en) | 2000-10-17 | 2002-11-26 | Ultra-Sonic Technologies, L.L.C. | Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation |
| US6553255B1 (en) | 2000-10-27 | 2003-04-22 | Aciont Inc. | Use of background electrolytes to minimize flux variability during iontophoresis |
| US6712805B2 (en) | 2001-01-29 | 2004-03-30 | Ultra Sonic Tech Llc | Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound |
| US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| US6750291B2 (en) | 2002-04-12 | 2004-06-15 | Pacific Corporation | Film-forming agent for drug delivery and preparation for percutaneous administration containing the same |
| US7052715B2 (en) | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| US7033998B2 (en) | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| US7291591B2 (en) | 2003-04-11 | 2007-11-06 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition |
| US6951658B1 (en) | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
| WO2007109347A2 (fr) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadhérine et ly6 e: cibles pour diagnostic et traitement du cancer |
| EP2091557A2 (fr) | 2006-11-15 | 2009-08-26 | Coda Therapeutics, INC. | Méthodes et compositions améliorées pour la cicatrisation des plaies |
| CN101835476B (zh) * | 2006-12-11 | 2016-08-17 | 科达治疗公司 | 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 |
| US20110144182A1 (en) | 2007-12-21 | 2011-06-16 | David Lawrence Becker | Treatment of surgical adhesions |
| CA2710375A1 (fr) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Traitement des conditions orthopediques |
| AU2008343758A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| US8975237B2 (en) | 2007-12-21 | 2015-03-10 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
| US20110038920A1 (en) * | 2008-01-07 | 2011-02-17 | Ryoichi Mori | Wound healing compositions and treatments |
-
2013
- 2013-03-26 CA CA2868534A patent/CA2868534A1/fr not_active Abandoned
- 2013-03-26 JP JP2015503477A patent/JP2015513905A/ja active Pending
- 2013-03-26 CN CN201380027990.1A patent/CN104736709A/zh active Pending
- 2013-03-26 WO PCT/US2013/033948 patent/WO2013148736A1/fr not_active Ceased
- 2013-03-26 EP EP13718667.2A patent/EP2831233A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2831233A1 (fr) | 2015-02-04 |
| JP2015513905A (ja) | 2015-05-18 |
| CN104736709A (zh) | 2015-06-24 |
| WO2013148736A1 (fr) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018200326B2 (en) | Improved methods and compositions for wound healing | |
| US20110038920A1 (en) | Wound healing compositions and treatments | |
| US20100279921A1 (en) | Impaired wound healing compositions and treatments | |
| JP2015057430A (ja) | 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用 | |
| CA2868534A1 (fr) | Compositions et traitements bases sur la modulation de la cadherine | |
| US20170056468A1 (en) | Treatment of resistant lesions | |
| US20160244759A1 (en) | Compositions and treatments based on cadherin modulation | |
| CA2940648A1 (fr) | Traitement des lesions resistantes | |
| CA2941140A1 (fr) | Traitement de lesions resistantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190326 |